secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950170-24-073322
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd announces VYD222 shows neutralizing activity against KP.1.1 and KP.3 SARS-CoV-2 variants
--------------------------------------------------------------------------------

- VYD222 demonstrated in vitro neutralization of KP.1.1 FLiRT and KP.3 variants in pseudovirus assays.
- Epitope at VYD222 binding interface is 99.8% conserved among 2024 GISAID sequences.
- Next candidate VYD2311 also shows continued in vitro neutralization against these dominant strains.
- FLiRT variants account for >50% of circulating SARS-CoV-2 sequences as of June 8, 2024.
- CDC predicts KP.3 will become the most dominant lineage nationally in the near term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/0000950170-24-073322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/ivvd-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer